Purified from tissue culture supernatant in an animal free facility
純化(Purification)
Protein A
保存(Storage)
Undiluted at 4°C in the dark
應(yīng)用(Reported Applications)
In vivo SIRPα blocking
In vitro SIRPα blocking
Western blot
Application References:
Yanagita, T., et al. (2017). 'Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy.' JCI Insight 2(1): e89140.
Koskinen, C., et al. (2013). 'Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling.' J Biol Chem 288(41): 29333-29344.
Teraoka, Y., et al. (2013). 'Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice.' PLoS One 8(3): e58359.
Zen, K., et al. (2013). 'Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state.' Nat Commun 4: 2436.
Lundberg, P., et al. (2007). 'Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.' Biochem Biophys Res Commun 352(2): 444-448.
Oldenborg, P. A., et al. (2001). 'CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.' J Exp Med 193(7): 855-862.
在線咨詢
電話咨詢
